Industry’s Flagship Forum Capturing Advancements Across Discovery, Preclinical, Translational, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics
2025 continues to deliver progress, fueled by innovations in new mechanisms of action to improve neurotransmission, promote neuroplasticity, alleviate side effects, and more. However, as unmet needs rise and inherent challenges of heterogeneity, translatability, and placebo responses remain largely unresolved, the field is left to wonder: was Cobenfy just a ‘one-off’, or are we on the verge of a new wave of transformative approvals?
Uniting 150+ discovery, preclinical, translational, clinical, and regulatory leaders, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications.
Recognized by key leaders as the "ideal size", offering a "targeted audience" perfect for meaningful networking and collaboration, join thought leaders from Bristol Myers Squibb, AbbVie, Otsuka, Johnson & Johnson, Biogen, Lundbeck, Delix Therapeutics, Boehringer Ingelheim and many more this September to revitalize the mental health drug development landscape.
Check Out the 2025 Agenda Now To:
- Learn more about this year's 40+ expert speakers
- Discover the all new EEG Focus Day & Investor's Panel
- Uncover the latest developments spanning depression, schizophrenia, anxiety, addiction and more
- Get a sneak preview of who will be attending this year's meeting
World-Class Speaker Faculty Includes
James Cronican
Head of Translational Medicine & Clinical Pharmacology for Neuroscience & Mental Health
Boehringer Ingelheim
Previously Attending Companies Include
What Did Previous Attendees Have to Say?
“An engaging and interactive conference, providing an opportunity for R&D leaders in neuropsychiatry to roll up their sleeves and discuss issues that we are collectively facing in this rapidly evolving field.”
Aaron Koenig, Chief Medical Officer, Delix Therapeutics
“Nice blend of emerging science, translational medicine and clinical development. Conference was not overwhelmingly large which allowed for great networking.”
Matt Kuntz, Vice President, Global Head of Regulatory Affairs, Neuroscience, AbbVie
Our Partners
Other Events in the World CNS Series
